Hui-Yao Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/537286/publications.pdf

Version: 2024-02-01

23 papers

573 citations

687363 13 h-index 713466 21 g-index

24 all docs

24 docs citations

times ranked

24

748 citing authors

#	Article	IF	CITATIONS
1	Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer, 2019, 128, 91-100.	2.0	81
2	Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey. Chinese Journal of Cancer, 2017, 36, 41.	4.9	74
3	Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review. Lancet Oncology, The, 2019, 20, e619-e626.	10.7	63
4	Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study. Lancet, The, 2016, 388, S10.	13.7	47
5	Medical and nonâ€medical expenditure for breast cancer diagnosis and treatment in China: a multicenter crossâ€sectional study. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 167-178.	1.1	45
6	Landscape and progress of global COVID-19 vaccine development. Human Vaccines and Immunotherapeutics, 2021, 17, 3276-3280.	3. 3	33
7	International trends in lung cancer incidence from 1973 to 2007. Cancer Medicine, 2018, 7, 1479-1489.	2.8	32
8	Medical expenditure for liver cancer in urban China. Journal of Cancer Research and Therapeutics, 2018, 14, 163-170.	0.9	28
9	Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011). Chinese Journal of Cancer, 2017, 36, 73.	4.9	27
10	Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey. Breast, 2018, 39, 53-62.	2.2	25
11	Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey. Lancet, The, 2016, 388, S29.	13.7	24
12	Economic burden of lung cancer attributable to smoking in China in 2015. Tobacco Control, 2020, 29, tobaccocontrol-2018-054767.	3.2	17
13	Clinical development of immuno-oncology in China. Lancet Oncology, The, 2020, 21, 1013-1016.	10.7	16
14	Medical expenses of urban Chinese patients with stomach cancer during 2002–2011: a hospital-based multicenter retrospective study. BMC Cancer, 2018, 18, 435.	2.6	14
15	Availability of anticancer biosimilars in 40 countries. Lancet Oncology, The, 2020, 21, 197-201.	10.7	13
16	Shortâ€ŧerm impact of breast cancer screening intervention on healthâ€ſelated quality of life in China: A multicentre crossâ€sectional survey. Psycho-Oncology, 2019, 28, 1836-1844.	2.3	9
17	Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review. Frontiers in Pharmacology, 2020, 11, 572569.	3.5	8
18	Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey. Cost Effectiveness and Resource Allocation, 2021, 19, 53.	1.5	7

#	Article	IF	CITATIONS
19	Healthâ€related quality of life of patients with colorectal neoplasms in China: A multicenter crossâ€sectional survey. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1197-1207.	2.8	5
20	Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours. BMJ Open, 2021, 11, e044543.	1.9	3
21	Trends on clinical characteristics and medical service use of lung cancer in China 2005–14: a multicentre retrospective survey. Lancet, The, 2017, 390, S25.	13.7	1
22	Sustainability of cancer screening in China: a multicentre assessment from the perspective of service suppliers and demanders. Lancet, The, 2017, 390, S95.	13.7	1
23	Epidemiological and economic evaluation of breast cancer screening in urban population in China: a multitarget calibrated modelling study. Lancet, The, 2019, 394, S58.	13.7	0